AstraZeneca (AZNCF, $99.60) vaccine linked to deadly blood clots in rare instances
The coronavirus vaccine developed by AstraZeneca PLC has been linked to an autoimmune reaction that can lead to deadly blood clots in rare instances, according to a study by researchers in Norway and Germany.
According to the researchers in Norway and Germany, the vaccine could trigger an autoimmune reaction that causes blood to clot in the brain, the Wall Street Journal reported. The research could lead to a possible treatment to prevent the problem, the paper said. Symptoms such as dizziness and blurred vision occur several days after the vaccine is administered. But the condition can be detected by a simple blood test and easily treated in a hospital, according to the report.
Last week, there was a brief halting of the AstraZeneca vaccine rollout in Europe after several people who received the vaccine died. But later in the week, EU regulators allowed the use of the vaccine, after assessing that benefits far outweighed the risks of the vaccine.
AZNCF in +1.75% Uptrend, rising for three consecutive days on January 08, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AZNCF advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on January 08, 2025. You may want to consider a long position or call options on AZNCF as a result. In of 118 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZNCF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.921) is normal, around the industry mean (5.632). P/E Ratio (36.101) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.124) is also within normal values, averaging (3.004). Dividend Yield (0.020) settles around the average of (0.164) among similar stocks. P/S Ratio (5.008) is also within normal values, averaging (3.643).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZNCF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
Industry PharmaceuticalsMajor